Introduction

W
hen the University of Michigan (UM) joined the ranks of the Clinical and Translational Science Award (CTSA) 1 consortium in 2007, the Michigan Institute for Clinical and Health Research (MICHR) was established to support the translation of medical advances throughout our institution. Th e importance of clinical research was recognized immediately and the clinical research unit (CRU), fi rst established in 1977, was embraced as the newly named MICHR Clinical Research Unit (MCRU) to form the hub of our clinical translation infrastructure. Concomitant with this move, MCRU reevaluated its business model and realized that it no longer matched closely with the rapidly evolving research portfolio, which was increasingly driven by epigenetics, epigenomics, and other population-based research. In response, MCRU established a new mobile clinical research team, named MCRU 2U, as a way to transfer the research skills and expertise of our clinical research staff to the chair or bedside of our research participants. Th e guiding metric embraced as an indicator of the MCRU 2U "valueadd" was the enablement of research that would be diffi cult or impossible to carry out in its absence. Th is paper outlines the steps taken in pursuit of this metric and the measure of its success, highlighting the impacts, benefi ts, and the lessons learned from 5 years of mobile clinical research at the University of Michigan.
Implementing a Mobile Clinical Research Team
With the ubiquitous funding squeeze across academic research institutions, hybrid academic-business models are evolving 2, 3 to meet the challenge of providing more and improved clinical research services with little or no increase in federal resources. Moreover, the growing population-based clinical research portfolio requires a larger and increasingly diverse participant population for successful completion, which means engaging more people from vulnerable groups for whom participation in clinical research represents additional barriers. 4 Although a relatively new concept, mobile clinical research teams are one exciting approach to address such issues and they are increasingly being employed to engage older populations who are confi ned to long-term care facilities, 5 to enroll and screen injection drug users, 6 to engage underserved ethnic populations, 7 and to service island communities. 8 Despite the rapidly growing interest in the concept of mobile clinical research this manuscript is, to our knowledge, the fi rst published description of initiating, sustaining and growing such a service. Mobilizing our clinical research has transformed the overall business model of our CRU from an infrastructure-based to a service-based model, positively impacting our stakeholders from Principle Investigators (PIs) to participants, particularly for historically under-represented populations. Our fi ndings may be useful to policymakers and university clinical research leadership who wish to adopt or expand the mobile clinical research model.
Th e main MCRU site is located in a specially designed, state-ofthe-art (2009) facility on the central campus, close to the Medical School, the main hospital, and a host of UM medical institutes. A satellite clinic provides facilities for the signifi cant participant population at the East Medical Campus (approximately 5 miles away), including outpatient examination rooms, nursing space, and specialized rooms and equipment shared with the Dental Research Unit. Our unit has fi ve participant beds for overnight stays (approximately 120 per year) and another fi ve that are just for ambulatory care (approximately 8,000 per year). Th e genesis of MCRU 2U was a single research study back in 2007, which required 200+ patients yet recruited only 20. Initially launched as an experimental approach to support this and other such "outlier" studies, MCRU 2U was activated just 145 times in the fi rst year. Th is new "helicopter research" style service quickly became indispensable however, and by 2012 the annual participant total had risen to almost 2,500, bringing the number of new participants served during the 5-year CTSA funding period to more than 5,000. Today MCRU 2U represents 20% of our overall business and has vastly strengthened our ability to service our PI constituency by increasing participation by targeted groups; participants from our Mott Children's Hospital are up from four per year to 285, while participants in our Comprehensive Cancer Center have risen from eight to 861 each year. Despite such intense growth, the basic foundations of our model have remained remarkably simple. Th e principles underlying MCRU 2U are primarily to:
• Extend the practice of clinical research to areas outside MCRU, to be inclusive of not only inpatients and outpatients, but also their friends and their family members.
• Provide vulnerable participants with safe and convenient access to the clinical research studies being carried out across our extensive hospital complex.
• Redesign the participant experience to increase enrollment and reduce dropout.
Th e ultimate success of a mobile clinical research team depends on the eff ectiveness of the implementation strategy. Figure 1 shows our Implementation Plan, which we have supplemented based on our experiences and the lessons we have learned. Th e fi rst step involves building a strong strategic case, and this means providing hard evidence to directly link each identifi ed need to the related service gap. Only by clearly demonstrating this link can the service gap form the basis of the impact analysis. In our case the research needs were driven by an increasingly population-based research portfolio, high in epigenetics and epigenomics studies. Participant recruitment and retention was another tactical challenge 9,10 and when we examined our service gaps we discovered that limiting our participant base to our clinical research infrastructure was restricting access to services for strategically important participant groups. In particular, this was impacting our growing portfolio of hospitalized cancer patients and newly diagnosed Phase I participants, who require support at the bedside because they are unable to travel to the CRU. Th ese issues added up to signifi cant lost opportunities for us in our strategic case.
The mainstay of our business case involved generating a cost-benefi t analysis to demonstrate that the proposal was justifi ed. In our experience, more than 70% of the procedures for which MCRU 2U is called upon are simple phlebotomy ( Figure 2 ). Th is is a very good indicator for assessing the return on investment (ROI) when introducing a mobile team; it can be largely a Medical Assistant (MA) driven service and the costs for phlebotomy supplies are modest ( Table 1 ) . Further, initiating and operating this service is highly cost eff ective because it involves no additional outlay for infrastructure costs. Th is cost calculation balances favorably against the potential opportunities in leveraging a huge new participant population, in addition to increasing the number and speed of study completions. In our case, our ROI has been profound and we have signifi cantly increased our business overall (see Figure 2 ) without increasing costs. Th e design of our business model was driven by our strategic case and we determined that the value-add to our clinical research enterprise, albeit in non-dollar form, was potentially so signifi cant that MCRU 2U should be fully funded through CTSA and institutional contributions. Th erefore, in order to fi rmly establish this new service, the PIs were not charged for activating the MCRU 2U team, with the intention of transitioning to a sustainable business model at a later date. At this point we undertook no direct advertising campaign which was, with hindsight, the right decision. Requests increased through word of mouth about as fast as we could grow to meet them, so more demand could have swamped our nascent service model. Implementation of this new service relied on the engagement of our most experienced staff . Clinical research nurses are highly specialized, operating at the front line of research eff orts, 11 and this in-depth knowledge put them in a critical position to form our Implementation Team and drive our Implementation Plan, by clearly communicating the responsibilities and metrics of each individual and then holding them accountable for the outcomes. Th eir expertise was balanced by multidisciplinary input from other stakeholders via our Advisory Team, which included not only associated PIs and leadership, but also ethics and regulatory representatives. Th is collaborative helped us identify known barriers and develop eff ective strategies to address them, as well as develop clear goals, expectations, milestones, and timelines. High level champions form a crucial part of this process because they work with institutional leadership and the wider research community to address resistance and act as "ambassadors" to promote the team's successes. As we progressed, the Advisory Team helped us to identify new barriers and quickly make improvements or changes as needed. Th e development of a regulatory compliance and document management system is of distinct importance during this stage of the implementation, since a mobile team can be particularly vulnerable in areas such as participant privacy and sample integrity. A key issue here is that we monitored our progress from the start, by defi ning a Metrics Map to ensure that the data we tracked were actually related to our success (or not!) via a direct link to our Key Deliverables.
12 Some of these measured core outcomes have evolved over the CTSA funding period and the major metrics we now use to evaluate growth and success are shown in Figure 2 a-c.
Although we did not actively advertise MCRU 2U, we did develop a Communication Plan by which MCRU PIs were made aware of the mobile services on off er and how they may access them. We off er four routes for MCRU 2U activation: (1) walk-in, where a PI may direct a participant to the CRU for immediate service; (2) Just-in-time, where a research team member is dispatched immediately to a hospital location external to the CRU; (3) prescheduled services at locations external to the CRU; and (4) the impromptu set-up of a temporary research "clinic" at any location. In terms of operation, the initial PI/study team request is assessed by MCRU staff and, depending on the complexity of the service requested, a Research Nurse or an MA is assigned. Importantly, when we introduced MCRU 2U we did not hire additional personnel, but instead reassigned and repurposed the original staff to incorporate this new service platform. We discovered that it is not feasible to identify a single individual to cover MCRU 2U requests because there are oft en multiple calls simultaneously for different locations. Even if several participants are in the same place, off ering a single MCRU 2U team member could mean an unacceptable wait for the last one to be seen. Since CRUs typically operate under a feast-or-famine model, an area of initial concern here was that having a number of staff on MCRU 2U calls without any lead time could compromise the operation of the unit. In practice however, we have found that the speed and fl exibility of the mobile team means we can work around them. In addition, we retain the right that, if required, the team member negotiates with the study team to redirect their participant to the unit, although in 5 years this has never been necessary. Over time we have developed working guidelines and best practices for the smooth operation of our service and, of the protocols we have developed, the most important are regulatory compliance, maintaining the chain of sample custody, and protecting the integrity of the sample (both physically and through documentation). Informed consent is protected in two ways with MCRU 2U; the fi rst is for scheduled visits, where informed consent documentation is confi rmed within the electronic medical records, and the second is for just-in-time appointments, where the documentation is provided to the MCRU 2U team member at the point of participant interaction, and is confi rmed before any service is carried out. In the case of our community nurse, informed consent can be carried out in two ways; the fi rst is before a scheduled visit, where the nurse can check the documentation in the electronic medical records or request a faxed copy. Th e second applies where the community nurse is participating in a population study, e.g., in a community center, where she partners with the study coordinator on-site and consent is obtained in real time. A particular strength of our model is that adaptations and improvements are made in real time through feedback during monthly meetings and it is fair to say that this is the foundation for much of our success in implementing and sustaining the team.
In the past 5 years we have consistently looked for innovative ways to service our clinical research studies better and we share here some of those which are, in our experience, the most valuable. Adding a community-based mobile research nurse, who travels up to 1 hour drive from our clinic, a distance of approximately 100 miles diameter, has built an additional layer of diversity into our participant base by avoiding exclusion on such criteria as social or economic grounds. However, because the resulting samples are obtained outside the regulated environment of the hospital they require new considerations, for example, regarding infection control and transport time. We have also found that pre-empting demand at strategic locations or time periods by setting up impromptu clinics is another highly effi cient approach for population-based studies. As an MA-driven service, and because our CRU off ers overnight services by a Research Nurse and an MA, we have extended our business model to off er a 24-hour MCRU 2U service at minimal cost. In addition, we are also looking at ways to network with primary care doctors who partner with researchers, as this is where patients will be seen repetitively.
Looking back over the past 5 years, we can clearly identify the three most crucial success factors for our mobile team. Almost Biohazard sharps container (small), gloves, band aids, towelettes (e.g., to clean area for urine collections), sample labels.
Biohazard sharps container (pint), gloves, band aids, towelettes (e.g., to clean area for urine collections), sample labels, blood pressure machine, and weight scale (kg).
Pager and/or mobile phone.
Documentation, * e.g., IRB paperwork, protocol specifi c clinical sheet.
Biohazard bags and ice pack for sample transport.
Biohazard bags for sample transport in specialized cooler.
Maps (for our vast hospital space), pens. Mapquest, GPS system, portable clipboard storage case, pens.
Backpack (some members opt for a rolling suitcase when additional equipment is required).
Rolling backpack and wheeled crate.
* Informed consent is not included here because this is verifi ed online before the visit or a copy is provided during the site visit. 
13.
Results of an internal survey carried out over 3 months (October to December 2011) and comprising 109 respondents .
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60% of participants recruited through MCRU 2U are new to research, many of whom had not planned to become a participant but agreed to participate in a study during a regular health service appointment. Th eir willingness to contribute largely rests on their participation not taking up a substantial amount of time and, as such, the leading key success factor for participants is speed. Th e average response for just-in-time MCRU 2U activations is just 19 minutes and this success is backed by survey measured impact, with 100% of MCRU 2U participants confi rming that they would recommend participation to a friend. 13 From the PI perspective, responsiveness is the critical success factor, particularly for studies with a rare or limited target population where they must be able to take advantage of every opportunity to recruit a new participant. Th is means being willing to travel to wherever the participant is located and off ering maximum fl exibility on the services off ered. MCRU 2U has six major centers within the UM health system where we regularly carry out services and for any other location, if we can physically get there, we will service a participant there. Similarly, if the need for a new service arises and it is physically possible to carry it out using equipment that can fi t in a backpack, we will off er it.
Conclusions and Future Prospects
MCRU 2U has positively impacted all our clinical research stakeholders and revolutionized the way our CRU does business. Researchers can now reach participants who would otherwise be inaccessible such as those in ICUs, and can more easily undertake complicated research studies such as those requiring the collection of time sensitive pharmacokinetics/biomarkers. The most important stakeholders however are the research participants and MCRU 2U participants are truly patients fi rst, representing populations that have historically been excluded from participating in research due to mobility, impairment, socioeconomic and other factors. MCRU 2U has signifi cantly reduced the barriers to participation for these groups.
Th e impact of the MCRU 2U service for this CTSA funding period is clear and, having had our award renewed in recent months, we are now looking forward to the next 5 years and even more progress. Th e breakneck pace at which technology is advancing means the population-based research portfolio will likely continue to grow rapidly, and mobile clinical research teams off er one of the most promising ways to meet the everincreasing demand for sample numbers. Clinical research is a critical and dynamic component of the translational pathway and CRUs throughout the CTSA are working hard to preempt future challenges, as we ask ourselves: How we can position our clinical research services for the next generation of clinical research?
